MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/healthcare12101017

Медицинская библиотека · Healthcare (Basel, Switzerland) · 2024

Efficacy and Safety of Bojungikgi-Tang for Persistent Allergic Rhinitis: A Randomized, Double-Blinded, Placebo-Controlled, Phase II Trial.

Lee Su Won, Woo Seong-Cheon, Lyu Yee Ran, Yang Won-Kyung, Kim Seung-Hyung, Kim Je Hyun, Kim Si Yeon, Kang Weechang, Jung In Chul, Kim Taesoo, Park Yang Chun

СтатьяПеревод пока не подготовлен

Аннотация

Conventional treatments for allergic rhinitis (AR) exhibit insufficiency and long-term use-related side effects. Considering the reported anti-inflammatory and immunoregulatory effects of Bojungikgi-tang (BJIGT), we aimed to assess its efficacy on persistent AR (PAR). Patients with PAR were randomly assigned in a 1:1:1 ratio into high-dose BJIGT, standard-dose BJIGT, and placebo groups, followed by 1-week run-in and 4-week treatment periods. The primary outcome included the mean change in Total Nasal Symptom Score (TNSS), with secondary outcomes encompassing the Korean Allergic Rhinitis-Specific Quality of Life Questionnaire, biomarkers, overall assessment, TNSS by AR pattern identification, and the Sasang constitution. The mean TNSS change was more improved in the BJIGT group than in the placebo group; however, no statistically significant differences were observed. Additional interaction effect analysis revealed a statistically significant improvement in the high-dose BJIGT group compared with the placebo group from weeks 1-2 to weeks 3-4. Regarding secondary outcomes, the BJIGT group exhibited similar or improved results compared with the placebo group, showing no statistically significant differences. No serious adverse effects or clinically significant changes in safety assessments were observed. Given that this study validated clinical improvement and safety, it serves as potential groundwork for pertinent future studies.

Для цитирования: Lee Su Won, Woo Seong-Cheon, Lyu Yee Ran, Yang Won-Kyung, Kim Seung-Hyung, Kim Je Hyun, Kim Si Yeon, Kang Weechang, Jung In Chul, Kim Taesoo, Park Yang Chun. Efficacy and Safety of Bojungikgi-Tang for Persistent Allergic Rhinitis: A Randomized, Double-Blinded, Placebo-Controlled, Phase II Trial.. Healthcare (Basel, Switzerland). 2024. DOI: 10.3390/healthcare12101017.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.